QDP301

QDP301 is an investigational drug candidate being developed by RestoriT for the treatment of muscle spasms. It is a proprietary formulation of cyclobenzaprine hydrochloride utilizing the company's Quick Dissolve Platform (QDP), which is designed to facilitate rapid oral or sublingual disintegration and absorption. By bypassing first-pass metabolism and providing a faster onset of action than traditional oral tablets, QDP301 aims to provide more efficient relief for acute muscle spasms. Cyclobenzaprine, the active ingredient, is a skeletal muscle relaxant that acts primarily on the locus coeruleus in the brain stem, where it antagonizes 5-HT2 receptors to reduce tonic somatic motor activity. The asset is currently part of RestoriT's clinical pipeline targeting musculoskeletal conditions.

Other names

QDP301-RestoriT-muscle spasmQDP-301-RestoriT-muscle spasmQDP 301-RestoriT-muscle spasm